A Study to Evaluate the Efficacy and Safety of Eltrombopag in Secondary Immune Thrombocytopenic Purpura (ITP)

Trial Profile

A Study to Evaluate the Efficacy and Safety of Eltrombopag in Secondary Immune Thrombocytopenic Purpura (ITP)

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2016

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jan 2016 New trial record
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top